BRUSSELS—The European Union blocked Illumina acquisition of Grail Inc., just days after the American life-sciences company won its case to do so in the U.S.
The $7.1 billion deal would have stifled innovation and reduced choice in an emerging market for early cancer-detection blood tests, the bloc’s antitrust regulator said.
